HUE054802T2 - Kodon-optimalizált, csökkentett méretû ATP7A cDNS és alkalmazások a rézszállítási zavarok kezelésére - Google Patents

Kodon-optimalizált, csökkentett méretû ATP7A cDNS és alkalmazások a rézszállítási zavarok kezelésére

Info

Publication number
HUE054802T2
HUE054802T2 HUE16794111A HUE16794111A HUE054802T2 HU E054802 T2 HUE054802 T2 HU E054802T2 HU E16794111 A HUE16794111 A HU E16794111A HU E16794111 A HUE16794111 A HU E16794111A HU E054802 T2 HUE054802 T2 HU E054802T2
Authority
HU
Hungary
Prior art keywords
codon
optimized
applications
treatment
reduced
Prior art date
Application number
HUE16794111A
Other languages
English (en)
Hungarian (hu)
Inventor
Stephen Kaler
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of HUE054802T2 publication Critical patent/HUE054802T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03004Cu2+-exporting ATPase (3.6.3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE16794111A 2015-10-21 2016-10-21 Kodon-optimalizált, csökkentett méretû ATP7A cDNS és alkalmazások a rézszállítási zavarok kezelésére HUE054802T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562244594P 2015-10-21 2015-10-21

Publications (1)

Publication Number Publication Date
HUE054802T2 true HUE054802T2 (hu) 2021-09-28

Family

ID=57256420

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16794111A HUE054802T2 (hu) 2015-10-21 2016-10-21 Kodon-optimalizált, csökkentett méretû ATP7A cDNS és alkalmazások a rézszállítási zavarok kezelésére

Country Status (12)

Country Link
US (3) US10988778B2 (enExample)
EP (1) EP3365438B1 (enExample)
JP (2) JP6854286B2 (enExample)
CN (1) CN108431216B (enExample)
AU (1) AU2016341983B8 (enExample)
CA (1) CA3001574A1 (enExample)
DK (1) DK3365438T3 (enExample)
ES (1) ES2879400T3 (enExample)
HU (1) HUE054802T2 (enExample)
PL (1) PL3365438T3 (enExample)
PT (1) PT3365438T (enExample)
WO (1) WO2017070472A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014594A1 (en) * 2018-07-12 2020-01-16 The Taxas A&M University System Compositions for the treatment of copper deficiency and methods of use
JP2024511999A (ja) * 2021-03-18 2024-03-18 シプリウム セラピューティクス インコーポレイテッド ヒスチジン酸銅組成物及びその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017321A1 (en) 1992-02-25 1993-09-02 Unisearch Limited Electrothermal atomic absorption and preconcentration device
DE69322847T2 (de) 1993-01-13 1999-05-27 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Monoklonaler Antikörper gegen menschliches Ceruloplasmin
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
KR100459644B1 (ko) 2001-03-31 2004-12-03 제노백(주) 혈액 여과지에서의 효소면역측정법을 이용한셀룰로플라스민 농도 측정 방법 및 이 방법을 이용한윌슨병 스크리닝 검사용 키트와 진단 시약
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
US20070161120A1 (en) 2006-01-10 2007-07-12 Viorica Lopez-Avila Ceruloplasmin Assay
JP5536445B2 (ja) * 2006-03-30 2014-07-02 ノバルティス アーゲー c−Metの抗体の組成物およびその使用方法
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
AU2009209408B2 (en) 2008-01-29 2015-06-11 Beacon Therapeutics Limited Recombinant virus production using mammalian cells in suspension
WO2010042102A1 (en) 2008-10-06 2010-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of subjects likely to benefit from copper treatment
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
WO2010071832A1 (en) * 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins

Also Published As

Publication number Publication date
AU2016341983A8 (en) 2022-10-06
CN108431216A (zh) 2018-08-21
US20180312871A1 (en) 2018-11-01
CA3001574A1 (en) 2017-04-27
US20250129382A1 (en) 2025-04-24
CN108431216B (zh) 2022-08-05
PL3365438T3 (pl) 2021-10-18
AU2016341983B2 (en) 2022-05-26
AU2016341983B8 (en) 2022-10-06
JP6854286B2 (ja) 2021-04-07
DK3365438T3 (da) 2021-07-12
ES2879400T3 (es) 2021-11-22
PT3365438T (pt) 2021-07-12
WO2017070472A1 (en) 2017-04-27
US12173306B2 (en) 2024-12-24
US20210214751A1 (en) 2021-07-15
AU2016341983A1 (en) 2018-04-26
JP2018533941A (ja) 2018-11-22
JP2021052796A (ja) 2021-04-08
EP3365438B1 (en) 2021-04-28
US10988778B2 (en) 2021-04-27
EP3365438A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
HUE066591T2 (hu) 8-ciano-5-piperidino-kinolinok, mint TLR7/8 antagonisták és alkalmazásuk immunrendellenességek kezelésére
GB201522315D0 (en) Securing webpages, webapps and applications
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
IL251279A0 (en) Electronic vaping device and components thereof
EP3120460A4 (en) Chips including classical and quantum computing processors
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
TWI560818B (en) Electronic package and the manufacture thereof
EP3440579A4 (en) INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
TWI563615B (en) Electronic package structure and the manufacture thereof
HUE036084T2 (hu) Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
PL3157901T3 (pl) Preparaty, ich wytwarzanie i zastosowanie, oraz odpowiednie składniki
EP3134653A4 (en) Heat pump and diswasher comprising the same
SI3270909T1 (sl) Kombinacije fiksnih odmerkov, ki obsegajo ETC1002 in en ali več statinov, za zdravljenje ali zmanjšanje kardiovaskularnega tveganja
GB2548842B (en) Snack food and manufacture thereof
HUE056408T2 (hu) Kombinációk és alkalmazásaik
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
AU360847S (en) Juicer
HUE054802T2 (hu) Kodon-optimalizált, csökkentett méretû ATP7A cDNS és alkalmazások a rézszállítási zavarok kezelésére
PL3464406T3 (pl) Struktura wielowarstwowa, jej wytwarzanie i zastosowanie
DK3374468T3 (da) Flamme- eller brandhæmmende midler og fremstilling og anvendelse deraf
IL263201A (en) Combination therapy comprising a polyunsaturated ketone and a folic acid partner
LT3364975T (lt) Trazodono ir gabapentino derinys, skirtas skausmo gydymui
LT3353164T (lt) Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui